Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Parra

Showing results (261-270 of 292) with videos related to

Pageof 30
Sort By:
Journal for Immunotherapy of Cancer|May 17, 2020
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validationJanis M Taube, Guray Akturk, Michael Angelo, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2020
<sup>18</sup>F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancerKyle G Mitchell, Behrang Amini, Yunfei Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2020
A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung CancerTina Cascone, Boris Sepesi, Heather Y Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2021
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant ChemoimmunotherapyMarta Casarrubios, Alberto Cruz-Bermúdez, Ernest Nadal, et al.
Cancer Discovery|April 18, 2025
Depletion of effector regulatory T cells associates with major response to induction dual immune checkpoint blockadeXianli Jiang, Nils-Petter Rudqvist, Bo Jiang, et al.
Nature Communications|August 20, 2021
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancerTina Cascone, Annikka Weissferdt, Myrna C B Godoy, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 14, 2023
Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non-Small Cell Lung CancerAlejandro Francisco-Cruz, Pedro Rocha, Alexandre Reuben, et al.
Journal for Immunotherapy of Cancer|July 22, 2024
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumorsMartin Wermke, Tobias A W Holderried, Jason John Luke, et al.
Blood Cancer Discovery|June 10, 2022
Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II ExpressionGuangchun Han, Qing Deng, Mario L Marques-Piubelli, et al.
Oncoimmunology|May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaZachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
Pageof 30

Showing results (261-270 of 292) with videos related to

Sort By:
Pageof 30
Journal for Immunotherapy of Cancer|May 17, 2020
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validationJanis M Taube, Guray Akturk, Michael Angelo, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2020
<sup>18</sup>F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancerKyle G Mitchell, Behrang Amini, Yunfei Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2020
A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung CancerTina Cascone, Boris Sepesi, Heather Y Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2021
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant ChemoimmunotherapyMarta Casarrubios, Alberto Cruz-Bermúdez, Ernest Nadal, et al.
Cancer Discovery|April 18, 2025
Depletion of effector regulatory T cells associates with major response to induction dual immune checkpoint blockadeXianli Jiang, Nils-Petter Rudqvist, Bo Jiang, et al.
Nature Communications|August 20, 2021
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancerTina Cascone, Annikka Weissferdt, Myrna C B Godoy, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 14, 2023
Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non-Small Cell Lung CancerAlejandro Francisco-Cruz, Pedro Rocha, Alexandre Reuben, et al.
Journal for Immunotherapy of Cancer|July 22, 2024
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumorsMartin Wermke, Tobias A W Holderried, Jason John Luke, et al.
Blood Cancer Discovery|June 10, 2022
Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II ExpressionGuangchun Han, Qing Deng, Mario L Marques-Piubelli, et al.
Oncoimmunology|May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaZachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
Pageof 30